Abstract:Osimertinib has demonstrated promising efficacy in T790M-positive NSCLC patients with central nervous system (CNS) metastases, but there is limited data on Chinese patients. We aim to investigate the efficacy and safety of osimertinib in T790M-positive advanced NSCLC patients with brain metastases and to explore the dynamic genetic changes as well as drug penetration in CNS with paired cerebrospinal fluid (CSF) and plasma samples. In this single arm, multi-center, prospective trial (NCT2972333), patients with confirmed EGFR T790M positive by Cobas, advanced NSCLC with brain metastases, who had progressed following first-generation EGFR-TKI treatment, received osimertinib 80 mg qd. The primary endpoint was overall progression free survival (PFSo). Paired CSF-plasma samples were collected at baseline, 6 weeks after treatment and disease progression and analyzed by NGS. Thirty-eight eligible patients were enrolled and 12 paired CSF-plasma samples were collected. Baseline characteristics and efficacy results are summarized in Table 1. Median PFSo (60% maturity, 23/38) was 8.4 months (95% CI 5.8-11.0). Adverse events of grade 3 or higher were reported in 39.5% patients. Analyzed in 12 paired samples, the median CSF penetration rate of osimertinib was 31.7% (range 19.8-57.7%), with a median CSF concentration of 10.83nM (range 5.2-30.3nM). T790M mutation was detected in 83% (10/12) of plasma and 17% (2/12) of CSF samples at baseline, with a concordance rate of 8.3% (1/12). Median PFSo was prolonged in patients with EGFR sensitizing mutation clearance at week 6 compared with those with persisting EGFR mutations (not reached vs 2.83 months; HR 0.09, 95% CI 0.02-0.54; p<0.01).Table 1Baseline characteristics and efficacyPatients characteristicsN=38Age, median (range), years63 (38-74)CNS metastases, No (%): brain metastases (BM) / leptomeningeal metastases (LM) / other35 (92.1%) / 2 (5.3%) / 1 (2.6%)Histology, No (%): adenocarcinoma38 (100%)EGFR mutations, No (%):T790M with Ex19del / L858R22(57.9%) /16 (42.1%)Sample type for T790M confirmation No (%): Blood / Tissue27 (71.1%) / 11 (28.9%)Lines of anti-tumor therapy, No (%): 1 / 2 / ≥313 (34.2%) / 3 (7.9%) / 22 (57.9%)EfficacyOverallExtracranialIntracranialMedian PFS (months, 95% CI)8.4 (5.8, 11.0)10.2 (7.5, 14.0)10.9 (6.1, NA)Objective response rate (ORR)42.4%(14/33)39.4%(13/33)71.9%(23/32)Disease control rate (DCR)90.9%(30/33)90.9%(30/33)96.9%(31/32)Median Duration of Response (DoR) (months, 95% CI)8.1 (3.4, NA)11.1 (5.6, 11.1)8.3 (5.8, NA) Open table in a new tab Osimertinib demonstrated promising efficacy, good blood brain barrier penetration and manageable tolerability in EGFR T790M-positive Chinese advanced NSCLC patients with brain metastases. NGS analysis revealed genetic heterogeneity between plasma and CSF samples and longitudinal genetic analysis may be beneficial to predict the efficacy of osimertinib.

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Osimertinib in Combination with Bevacizumab in EGFR-Mutated NSCLC with Leptomeningeal Metastases

Treatment Response to Osimertinib in EGFR-Mutated Leptomeningeal Metastases from Non-Small Cell Lung Cancer: A Case Series.

Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study

Ott_a_199452 7785..7790

Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed

P3.13-17 A Retrospective Study: Central Nervous System Response to Osimertinib in Patients with Advanced NSCLC

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Safety and Efficacy of Osimertinib Plus Bevacizumab As First-Line Treatment in EGFRmutated NSCLC with Brain Metastasis Instructed by Dynamic Monitoring Circulating Tumor DNA of Paired Cerebrospinal Fluid and Plasma

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial

Data from Real World to Evaluate the Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC

P1.13-25 Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study)

Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments

Molecular characteristics and treatment strategy in advanced, EGFR-mutant non-small cell lung cancer with concomitant BRAF variations.

Brain Metastatic Outgrowth and Osimertinib Resistance Are Potentiated by RhoA in EGFR-mutant Lung Cancer

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies